一例口腔癌术后肺转移患者发生的胆管炎，作为纳武单抗诱导的免疫相关不良事件
A Case of Cholangitis as a Nivolumab-Induced Immune-Related Adverse Event in a Patient with Pulmonary Metastasis After Surgery for Oral Cancer.
作者信息
Fukuzawa Satoshi, Yamagata Kenji, Uchida Fumihiko, Endo Masato, Sakamoto Noriaki, Bukawa Hiroki
机构信息
Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575 Japan.
Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
出版信息
J Maxillofac Oral Surg. 2024 Aug;23(4):979-983. doi: 10.1007/s12663-023-01976-7. Epub 2023 Jul 26.
Abstract
We report a case of cholangitis, an immune-related adverse event (irAE), caused by the administration of nivolumab in a patient with lung metastasis of oral cancer. A 72-year-old man developed pulmonary metastasis after surgery for oral cancer. Hepatic enzyme abnormalities were observed after the second session of treatment, and irAE cholangitis was diagnosed based on the results of the blood test results and endoscopy findings. We suggested steroid treatment, but the patient refused it. Therefore, he was treated with ursodeoxycholic acid. The cholangitis gradually deteriorated, the patients' general condition worsened, and he died 169 days after the onset of cholangitis.
摘要
我们报告了一例由纳武单抗给药引起的胆管炎病例，这是一种免疫相关不良事件（irAE），发生在一名患有口腔癌肺转移的患者身上。一名72岁男性在口腔癌手术后发生了肺转移。在第二次治疗后观察到肝酶异常，并根据血液检查结果和内镜检查结果诊断为irAE胆管炎。我们建议进行类固醇治疗，但患者拒绝了。因此，他接受了熊去氧胆酸治疗。胆管炎逐渐恶化，患者的一般状况变差，在胆管炎发作169天后死亡。
相似文献
1
A Case of Cholangitis as a Nivolumab-Induced Immune-Related Adverse Event in a Patient with Pulmonary Metastasis After Surgery for Oral Cancer.一例口腔癌术后肺转移患者发生的胆管炎，作为纳武单抗诱导的免疫相关不良事件
J Maxillofac Oral Surg. 2024 Aug;23(4):979-983. doi: 10.1007/s12663-023-01976-7. Epub 2023 Jul 26.
2
Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study.嗜酸性粒细胞是肾细胞癌患者接受伊匹木单抗联合纳武单抗治疗所致严重免疫相关不良事件的预测指标：一项回顾性多中心队列研究。
Front Immunol. 2025 Jan 9;15:1483956. doi: 10.3389/fimmu.2024.1483956. eCollection 2024.
3
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤（使用RobotReviewer软件进行的快速综述）
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.
4
Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.原发性胆汁性胆管炎的药物干预：一项网状Meta分析尝试
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011648. doi: 10.1002/14651858.CD011648.pub2.
5
Immune Checkpoint Inhibitor-Induced Myositis, Myocarditis, and Myasthenia Gravis Overlap Syndrome Following Nivolumab and Ipilimumab Combination Therapy in a 60-Year-Old Male With Metastatic Renal Cell Carcinoma.一名60岁转移性肾细胞癌男性患者在接受纳武单抗和伊匹单抗联合治疗后出现免疫检查点抑制剂诱导的肌炎、心肌炎和重症肌无力重叠综合征。
Cureus. 2025 Jul 16;17(7):e88101. doi: 10.7759/cureus.88101. eCollection 2025 Jul.
6
IgG4-related disease with interstitial nephritis in a patient with metastatic melanoma following immune checkpoint inhibitor treatment: a case report.免疫检查点抑制剂治疗后转移性黑色素瘤患者并发IgG4相关性疾病伴间质性肾炎：一例报告
BMC Rheumatol. 2025 Aug 1;9(1):95. doi: 10.1186/s41927-025-00548-1.
7
Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report.巨大肝细胞癌转化治疗期间的肿瘤标志物假性进展及免疫相关胆管炎：一例报告
Front Immunol. 2025 Jun 4;16:1529016. doi: 10.3389/fimmu.2025.1529016. eCollection 2025.
8
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
9
Short-course oral steroids alone for chronic rhinosinusitis.短期口服类固醇单独用于慢性鼻窦炎。
Cochrane Database Syst Rev. 2016 Apr 26;4(4):CD011991. doi: 10.1002/14651858.CD011991.pub2.
10
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.免疫相关不良反应作为免疫检查点抑制剂疗效的替代指标：一项随机研究的系统评价和荟萃分析。
ESMO Open. 2023 Apr;8(2):100787. doi: 10.1016/j.esmoop.2023.100787. Epub 2023 Feb 24.
本文引用的文献
1
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.帕博利珠单抗治疗复发性/转移性头颈部鳞状细胞癌的疗效和安全性：KEYNOTE-012 长期随访后的汇总分析。
Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.
2
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.纳武利尤单抗对比研究者选择的方案治疗复发性或转移性头颈部鳞状细胞癌：CheckMate 141 研究 2 年长期生存随访结果更新，且根据肿瘤 PD-L1 表达进行分析。
Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.
3
Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.纳武利尤单抗二线化疗治疗晚期非小细胞肺癌后发生胆管梗阻：病例报告。
Cancer Immunol Immunother. 2018 Jan;67(1):61-65. doi: 10.1007/s00262-017-2062-3. Epub 2017 Sep 14.
4
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.尼伏单抗相关胆管炎在非小细胞肺癌患者的影像学和临床病理特征。
Invest New Drugs. 2017 Aug;35(4):529-536. doi: 10.1007/s10637-017-0453-0. Epub 2017 Mar 20.
5
Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury.纳武单抗诱导的胆管炎肝病：一种新型严重肝损伤形式。
Ann Oncol. 2017 Mar 1;28(3):671-672. doi: 10.1093/annonc/mdw649.
6
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.纳武利尤单抗用于复发性头颈部鳞状细胞癌
N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
7
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.抗 CTLA-4 和抗 PD-1 抗体单药及联合治疗的安全性特征。
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. doi: 10.1038/nrclinonc.2016.58. Epub 2016 May 4.
8
Management of toxicities of immune checkpoint inhibitors.免疫检查点抑制剂毒性的管理。
Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6.
9
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.免疫检查点抑制剂在临床实践中的应用：免疫相关毒性管理的最新进展。
Transl Lung Cancer Res. 2015 Oct;4(5):560-75. doi: 10.3978/j.issn.2218-6751.2015.06.06.
10
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.一项开放标签、单臂、II 期临床试验，评估 zalutumumab（一种人源化抗 EGFR 单克隆抗体）在铂类耐药的头颈部鳞状细胞癌患者中的疗效。
Cancer Chemother Pharmacol. 2014 Jun;73(6):1227-39. doi: 10.1007/s00280-014-2459-z. Epub 2014 Apr 9.
Zotero 插件